Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
- 15 August 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (16) , 5928-5934
- https://doi.org/10.1158/1078-0432.ccr-05-0130
Abstract
Purpose: Tumor responses in early-phase trials are used to determine whether new agents warrant further study. Given that spontaneous regressions are observed in melanoma and renal cell carcinoma, this study assessed whether tumor responses, particularly in these two tumor types, predict for future regulatory drug approval.Keywords
This publication has 16 references indexed in Scilit:
- Current treatment of renal cell carcinomaAnnals of Oncology, 2004
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?European Journal Of Cancer, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Placebo‐associated remissions in a multicentre, randomized, double‐blind trial of interferon γ‐1b for the treatment of metastatic renal cell carcinomaBJU International, 2000
- Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysisThe Lancet, 2000
- Spontaneous Regression of Metastatic Renal CancerAmerican Journal of Clinical Oncology, 1997
- Spontaneous regression of cancerCancer Treatment Reviews, 1996
- Metastatic Malignant Melanoma with Spontaneous and Complete Regression of the Primary LesionThe Journal of Dermatologic Surgery and Oncology, 1994
- Statistical Model to Determine the Relationship of Response and Survival in Patients With Advanced Ovarian Cancer Treated With ChemotherapyJNCI Journal of the National Cancer Institute, 1992
- Response rates, duration of response, and dose response effects in phase I studies of antineoplasticsInvestigational New Drugs, 1991